Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

NCT02764125 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Stalevo
DRUG: levodopa MR

Sponsor

Orion Corporation, Orion Pharma